Brain endothelial cells (BEC) have unique anatomic features that restrict the passage of hematogenous cells from the circulation to the brain. However, in the course of the inflammatory reactions that occur during brain tissue damage, infections, or autoimmune diseases, BEC mediate the recruitment and infiltration of leukocytes (Schroeter et aI., 1995; Iadecola et aI., 1995 Iadecola et aI., , 1996 Galea et aI., 1998a) . This process is initiated by adhesion mol-creased NOS-2 protein expression. For both ICAM-I and NOS-2, mRNA expression correlated with protein expression. Block ade of NOS activity with L-N-monomethylargiuine (L-NMMA) did not alter ICAM-I expression, indicating that the nitric oxide released by NOS-2 did not cause the down-regulation of lCAM-I. Analysis of NFKB activation indicated that cAMP acted through a mechanism other than inhibition of nuclear trans location of NFKB. The authors conclude that cAMP modulates the expression of proinflammatory molecules in brain endothe lium. This suggests that inflammatory processes at the blood brain barrier in vivo may be regulated by perivascular neuro transmitters via cAMP. Key Words: Blood-brain barrier Inflammation-Adhesion molecule-Nitric oxide synthase 2-Interleukin-l [3-Interferon-,),-NFKB-L-NMMA.
ecules like the intercellular adhesion molecule-l (ICAM I), a cell surface glycoprotein of the immunoglobulin superfamily that binds to r3-integrins present in leuko cytes (Diamond et aI., 1990) . Increased ICAM-I expres sion has been detected in ischemia (Schroeter et aI., 1995) , experimental allergic encephalomyelitis (Steffen et aI., 1994) , multiple sclerosis (Cannella and Raine, 1995) , and acquired immunodeficiency syndrome-re lated dementia (Nottet et aI., 1996) . Along with adhesion molecules, BEC can express the calcium-independent type of nitric oxide synthase (NOS-2) in the course of brain inflammatory processes (Dorheim et aI., 1994; Iadecola et aI., 1996; Galea et aI., 1998b) . The appear ance of both ICAM-l and NOS-2 in BEC probably is induced by proinflammatory cytokines like interleukin-1 r3 (IL-I r3), tumor necrosis factor (TNF), or interferon-), (IFN-)') produced by either brain cells or infiltrated leu kocytes (Buttini, 1994; Benveniste, 1994) .
Blockade of ICAM-l lessens the severity of experi mental allergic encephalomyelitis (Archelos et aI., 1993; Morrisey et aI., 1996) and decreases the size of the in-farctions caused by cerebral ischemia (Chopp et aI., 1996; Soriano et aI., 1996) , demonstrating that leukocyte infiltration exacerbates these diseases. By contrast, the nitric oxide (NO) derived from endothelial NOS-2 can have both detrimental and beneficial effects. On the one hand, it could contribute to the damage by reacting with superoxide molecules, thereby generating peroxynitrites, highly cytotoxic agents (Lipton et aI., 1998) . On the other hand, NO could provide protection by inducing vasodilation (Loscalzo et aI., 1995) and inhibiting leu kocyte adhesion and platelet aggregation (Radomski et a!., 1987; Kubes et aI., 1991; Lefer et aI., 1999) . Local regulation of ICAM-l and NOS-2 expression thus may alter the outcome of brain inflammatory diseases.
Cyclic adenosine monophosphate (cAMP) is a ubiq uitous regulator of inflammatory and immune reactions. Thus, cAMP can block lymphocyte activation (Birch and Pol mar, 1982; Jegasothy et aI., 1978) , inhibit proinflam matory cytokine release from macrophages (Knudsen et aI., 1986; Kunkel et aI., 1988) , and reduce expression of adhesion molecules in peripheral endothelial cells (De Luca et a!., 1994; Ghersa et aI., 1994) and astrocytes (Ballestas and Benveniste, 1997) . By contrast, cAMP can either stimulate (Sowa and Przewlocki, 1994; Eberhardt et a!., 1998) or inhibit (Feinstein et a!., 1993; Andersen et a!., 1996) NOS-2 expression, depending on the cell type (for review see Galea and Feinstein, 1999) .
Brain endothelium in culture has adenylate cyclase coupled receptors (Bacic et a!., 199 1, Durie-Trautmann et aI., 199 1) and, in vivo, is innervated by noradrenergic, serotonin, and VIP-ergic fibers (Cohen et aI., 1997; Pas palas and Papadopoulos, 1998) , indicating the existence of local exposure to cAMP-elevating neurotransmitters. It is thus conceivable that cAMP may regulate the ex pression of inflammatory molecules in BEC, as it does in other cell types. To test this idea, we determined whether cAMP-dependent signaling affects the cytokine mediated expression of ICAM-l and NOS-2 mRNA and proteins in cultured BEC. Studies were performed in both primary cultures and in the immortalized BEC cell line GP8.3 (Greenwood et aI., 1996) . We found that the increase in intracellular cAMP potentiated the cytokine induced expression of NOS-2 mRNA and protein, whereas it reduced that of rCAM-I. These observations suggest that cAMP may be a biological modulator of inflammatory processes at the blood-brain barrier.
MATERIALS AND METHODS

Brain endothelial cell cultures
Primary cultures. Cells were obtained following a previously described procedure (Abbott et a!., 1992) with modifications. Two-month-old male Sprague Dawley rats were lightly anes thetized with halothane and decapitated. Brains were dissected out of the skulls and placed in buffer A (DMEM, 20 mmol/L Hepes buffer pH 7.6, 100 lU/mL penicillin, and 100 f.Lg/mL streptomycin). The meninges and the choroid plexus were peeled off, and the cerebral cortices were isolated, finely chopped with scalpels, and incubated for I hour at 37°C in buffer A containing 0.5% bovine serum albumin, I mglmL collagenase/dispase (Sigma, St. Louis, MO, U.S.A.), 20 U/mL DNAse I (type II, Sigma), and 0. 15 f.Lg/mL protease inhibitor TCLK (Sigma). The suspension was briefly centrifuged, the pellet resuspended in buffer A containing 13% dextran, and centrifuged for 10 minutes at 5,800 x g at 4°C in a swinging bucket rotor. The resulting pellet containing brain parenchymal microvessels was saved, and the remaining tissue was resus pended and centrifuged twice to increase the yield. The mi crovessel pellets were pooled, resuspended in buffer A contain ing collagenase/dispase, and incubated for 2 hours at 3rC with gentle shaking. The incubation was halted by addition of buffer A, and the vessels were collected by brief centrifugation and seeded on plates coated with 0.1 % bovine collagen (Sigma). Culture media consisted of high-glucose (25 mmollL) DMEM (GIBCO, Gaithersburg, MD, U.S.A.) containing 20 mmol/L Hepes, pH 7.4, and supplemented with 100 f.Lg/mL heparin (Sigma), 100 f.Lg/mL human endothelial cell growth supple ment (ECGS), 10% heat-inactivated fetal calf serum (Atlanta Biologicals, Atlanta, GA, U.S.A.), and 10% rat serum. The autologous serum significantly increases the proliferation rate of the cells (Balyasnikova et aI., in preparation). Rat serum was routinely prepared from the rats used for microvessel prepara tions. Blood was extracted, centrifuged at 6000 x g for 30 minutes at 4°C, and the serum sterilized with a O.I-f.LM filter. The cells were grown up to confluency (7 to 10 days), the media being changed every other day. Brief exposure to Ca++ and Mg++-free Hanks buffered saline on day 2 or 3 was carried out to remove contaminant cells, which were large cells with mUltiple processes, perhaps fibroblasts. Examination of conflu ent cultures under a phase contrast microscope revealed mostly uniform monolayers of intensely refringent cells with the spindle shapes characteristic of endothelial cells. The endothe lial nature of the cultures was confirmed by immunohistochem ical analysis of the presence of the endothelial marker factor VIII (antibody purchased from DAKO, Carpinteria, CA, U.S.A.). Occasionally, contaminating cells appeared either on top of the endothelial monolayers or forming colonies, although they never amounted to more than 10% of the total number of cells.
Immortalized endothelial cells. The generation and charac terization of these cells, clone GP8.3, have been described else where (Greenwood et a!., 1996) . The cells were plated in 0.1 % bovine collagen and grown in high-glucose DMEM supple mented with 20% heat-inactivated fetal calf serum, 50 f.Lg/mL human brain ECGS, and 100 f.Lg/mL heparin. Cells were pas saged by a brief digestion of 0.05 mmollL trypsin and used between passages 10 and 12.
Quantification of NOS-2 and IeAM-! proteins
The expression of the NOS-2 protein was estimated by mea suring the accumulation of nitrites in the culture media using the Griess reagent (Green et aI., 1982) . The expression of cell surface ICAM-l was assessed by ELISA. Cells were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS), pH 7.0, for 20 minutes at room temperature. They then were incu bated with PBS containing 0.5% casein for 30 minutes at 4°C and were incubated with a monoclonal antibody against rat ICAM (clone lA29, PharMingen, San Diego, CA, U.S.A.) in PBS/0.5% casein overnight at 4°C. The concentration of the antibody used, 3 f.Lg/mL, was found in pilot experiments to detect cell surface ICAM-l within the linear range. Cells were incubated in parallel with nonimmune mouse IgG (Sigma) as a 1. V. BALYASNIKOVA ET AL. negative control. Cells then were incubated for I hour with 1: 1,000 goat anti-mouse antibody conjugated to alkaline phosphatase (Sigma) and diluted in PBS/O.5% casein. The al kaline phosphatase substrate (Sigma) was added, and the cells were incubated at room temperature until the reaction devel oped. Then, the OD405 was measured in a 96-well plate reader. ICAM-I contents are expressed as relative to the constitutive expression detected by the immunocytochemical reaction.
RNA isolation and reverse transcriptase polymerase chain reaction analysis
We followed procedures that have been previously described (Gilliland et aI., 1990; Galea et aI., 1998a) . Total cytoplasmic RNA was isolated from cells by homogenization in hyperos motic Tris-HCI buffer, digestion in proteinase K, extraction in phenol-chloroform, and isopropanol precipitation. Synthesis of cDNA was carried out in the presence of random primers using Superscript reverse transcriptase (GIBCO). Samples were am plified by polymerase chain reaction (PCR) using 35 cycles consisting of denaturation at 93°C for 30 seconds, annealing at 60°C for 45 seconds, and synthesis at noc for 45 seconds. The PCR products were separated by electrophoresis through a 2% agarose gel with ethidium bromide. All PCR reactions were carried out in a Hybaid Thermal Reactor (Denville Scientific, Denville, NJ, U.S.A.) controlled by tube temperature. For semi quantification, PCR reactions contained a single amount of internal standards for NOS-2 (0.1 fg), ICAM-I (1 fg). The PCR products were separated by electrophoresis in 2% agarose and quantitated using a computer image analysis system (Biorad).
Electrophoretic mobility assays
To determine whether NFKB may play a role in the regula tory actions of cAMP, we studied by electrophoretic mobility assay (EMSA) the effect of cAMP on the cytokine-stimulated translocation of NFKB to the nucleus.
Preparation of nuclear extracts. The cells were washed with ice-cold PBS, scraped out of the plates, collected by brief cen trifugation, resuspended in buffer A (which contained 10 mmollL Hepes buffer pH 7.9, 1.5 mmollL MgCI 2 , 10 mmollL KCI, 0.5 mmol/L dithiothreitol, and 0.5 mmollL phenylmeth ylsulfonylfluoride), and placed on ice for 10 minutes. Then, nonidet P-40 was added (final concentration 0.6%), and cells were vortexed for 10 seconds. The nuclei were collected by brief centrifugation in a microcentrifuge, the supernatants dis carded, and the nuclei were washed once with buffer A and collected again by centrifugation. To obtain nuclear protein extracts, the nuclei were incubated in buffer B (20 mmollL Hepes buffer, 25% glycerol, 420 mmollL NaCl, 0.2 mmollL ethylenediamine tetraacetic acid [EDTAJ, 0.5 mmollL dithio threitol, and 0.5 mmollL phenylmethylsulfonylfluoride) at 4°C for 30 minutes with gentle rocking. The suspensions were cen trifuged at 15,000 x g for IS minutes at 4°C, and the superna tants stored at -80°C. Protein concentrations were measured by the Bradford method.
EMSA procedure. The NFKB oligonucleotides (5 pmol) cor responding to the palindromic consensus sequences were end labeled with 10 f.LCi ['Y3 2 Pl-ATP (New England Nuclear, Bos ton, MA, U.S.A.) and 10 U T4 polynucleotide kinase (Pro mega), and purified in G-50 Sephadex columns (Pharmacia, Piscataway, NJ, U.S.A.). Nuclear extracts (5 to 10 f.Lg protein) were incubated with the radiolabeled oligonucleotide (20,000 to 100,000 cpm) in a final volume of 20 f.LL in the presence of 1 f.Lg poly dldC, 20 mmollL Hepes buffer pH 7.9, I mmollL EDTA, 5% glycerol, 100 mmollL NaCl, and 0.5 mmollL dithiothreitol. Incubations were carried out for 20 minutes at room temperature. DNA-protein complexes were resolved by
electrophoresis (150 V) in 4% nondenaturing polyacrylamide gels using 0.5x Tris-Borate-EDTA as the running buffer. Con trol for nonspecific binding was carried out using mutant NFKB oligonucleotides instead of consensus ones. Sequences of oli gonucleotides (double-stranded) were as follows: consensus NFKB, 5' AGT TGA GGG GAC TTT CCC AGG C-3; and mutant NFKB, 5' AGT TGA GGC GTI TIT CCC AGG C-3' (Santa Cruz Biotechnology).
RESULTS
Effect of IL-ll3 and IFN-'Y on the expression of NOS-2 and ICAM-l proteins
Primary cultures. Cells were exposed to IL-lj3 (1 to 100 ng), IFN-l' (l to 100 U/mL), or combinations of the two cytokines. Protein expression for ICAM-I and NOS-2 was measured 24 hours later. No significant basal production of nitrites was detected, indicating lack of constitutive expression of the NOS-2 protein. The result also indicates that the amount of nitrite accumulation from the NOS-3 constitutively present in the cells (data not shown) is undetectable. IL-I 13 alone increased nitrite accumulation to detectable levels, although not statisti cally significant compared with the basal expression. Ad dition of IFN-l' significantly potentiated the effect of IL-J 13 by eightfold (Fig. I) . By itself, IFN-l' had no effect, suggesting that IFN-l' can "prime" the effect of other cytokines on NOS-2 expression, an effect well documented in several cell types (Feinstein et aI., 1994; Martin et aI., 1994) .
Unlike NOS-2, the ICAM-I protein was constitutively present in the endothelial cell membrane (Fig. 1, black  bars) . IL-Jj3 (l00 ng/mL) increased ICAM-l content by twofold. Alone, IFN-l' (100 U/mL) did not induce ICAM-I expression, nor did it potentiate the effect of IL-lj3. Instead, it caused a small but statistically signifi cant decrease of the IL-J j3-mediated effect.
Immortalized brain endothelial cells. No constitutive NOS-2 expression was detected in the immortalized BEe. Although neither IL-lj3 (l ng/mL) nor IFN-l' (10 and 100 U/mL) induced nitrite release on their own, together they synergized to induce NOS-2 expression (Fig. 2) . In contrast, ICAM-I protein was constitutively present in the cell surface, and its expression was increased by ap proximately 70% by 1 ng/mL IL-I 13. No further increase was observed by greater concentrations of IL-Ij3. The IFN-l' alone (10 and 100 U/mL) did not induce ICAM-l expression, nor did it potentiate the effect of IL-I 13.
Effect of cAMP on the expression of ICAM-l and
NOS-2 proteins
Eff ect on NOS-2 expression Primary endothelial cells. In primary cultures, stimu lation of cAMP-dependent pathways with dibutyryl cy clic AMP (dbcAMP; 1 mmollL) or forskolin (100 /-Lmoll L) did not increase the release of nitrites over basal lev els. By contrast, both drugs increased by twofold the 
Effect of cytokines and cAMP-elevating agents on the expression of NOS-2 and ICAM-1 proteins in primary endothelial cell cultures. Cells were exposed to four different treatments: (1 ) DMEM alone; (2) IL-1 �; 100 ng/mL alone or together with IFN--y; 100 U/mL; (3) cytokines plus forskolin or dbcAMP; or (4) forskolin or dbcAMP alone. NOS-2 and ICAM-1 protein expression was assessed 24 hours later by the release of nitrites and ELISA, respectively. Notice that responses to IL-1 � and IL-1 �/IFN--y are displayed at different scales. The "DMEM" group was used as the blank for "cytokines," whereas "forskolin or dbcAMP alone" was the blank of "cytokines plus forskolin or dbcAMP. content of nitrites in cells incubated with IL-I[3 (Fig. I) , suggesting that cAMP stimulates the expression of NOS-2. Unexpectedly, cAMP did not affect the induction of NOS-2 caused by the exposure to IL-I[3 and IFN--y com bined (Fig. I ). I. V. BALYASNIKOVA ETA/.:,.
by forskolin reproduced the effects of dbcAMP (Fig. 3) . Thus, exposure to I to 100 f.LmollL forskolin enhanced nitrite release up to three times. The two largest doses tested, 10 and 100 J.LmollL, potentiated NOS-2 expression equally.
Effect on ICAM-l expression. Primary cultures. Exposure to 1 mmollL db cAMP had no effect on the constitutive ICAM-l expression, but it significantly (P < 0.05) decreased the TL-II3-induced expression by approximately 75% and caused the IL-1131 IFN -')I-induced expression to fall below basal levels (Fig. I) . Forskolin elicited a smaller reduction in the IL-II3-induced ICAM-I expression compared with db cAMP. The resulting ICAM-I expression was not statis tically different from control.
Immortalized cells. The cAMP analog dbcAMP (0.1 to 1 mmollL) had no effect on the constitutive expression of ICAM-I, but it decreased the cytokine-induced ex pression in a dose-dependent and statistically significant manner (Fig. 3) . Maximal inhibition, approximately 65%, was observed at 1 mmol/L dbcAMP. Forskolin (I to 100 f.Lmol/L) also reduced the cytokine-induced up regulation of ICAM -I in a dose-dependent manner (Fig.  3) . At the highest concentration tested, 100 f.Lmol/L, for skolin completely abolished the cytokine-induced ex pression and reduced the constitutive expression of the adhesion molecule.
These results indicate that in both primary and immor talized BEC, stimulation of cAMP-dependent pathways respectively potentiate and inhibit the cytokine-induced expression of NOS-2 and TCAM-I. Effect of cAMP on ICAM-! and NOS-2 mRNA steady-state contents
To determine whether cAMP alters the expression of NOS-2 and ICAM-I mRNA, immortalized endothelial cells were incubated with IL-113 (20 ng/mL) plus IFN-')I (l00 U/mL) in the presence and absence of O.l mmollL dbcAMP. Five hours later, a time at which maximal ex pression of NOS-2 occurs after inflammatory activation (Galea et aI., ]994), cells were processed to measure contents of ICAM-I and NOS-2 mRNA by semiquanti tative PCR. Consistent with the protein expression, non stimulated cells showed constitutive expression of ICAM-I but not NOS-2 mRNA. On exposure to cyto kines, both mRNA were upregulated (Fig. 4) . The db cAMP did not have an effect on its own, but it modified the cytokine-mediated expression: NOS-2 mRNA was upregulated approximately three times, whereas TCAM-I mRNA was decreased by approximately 50%. That is, the changes in mRNA contents induced by cAMP dependent pathways correlated with the changes in pro tein expression.
Does NOS-2-derived NO mediate the decrease in ICAM-! expression induced by cAMP?
In peripheral endothelium, NO inhibits the expression of adhesion molecules by blocking NFKB activation (De Caterina et aI., 1995; Lefer et aI., 1999) . To determine whether the cAMP-induced increase in NO production by NOS-2 could account for the parallel decrease in ICAM-I expression in BEC we examined the following possibilities: (1) if inhibition of NOS-2 activity by the and NOS-2 protein expression in immortalized BEC (clone GPS.3). Cells were incubated for 24 hours with DMEM alone, IL-1 J3 (1 00 ng/mL) alone or together with IFN-), (1 00 U/mL), cytokines plus forskolin or dbcAMP, or forskolin or dbcAMP alone. The "OM EM" group was used as the blank for "cyto-0 10 100
kines," whereas "forskolin or IL-l� ng/ml dbcAMP alone" was the blank
of "cytokines plus forskolin or dbcAMP." Activation of cAMPdependent pathways decreased ICAM-1 but increased NOS-2 protein expression. Exposure to dbcAMP or forskolin had no effect. Immortalized cells were stimulated with IL-113 (100 ng/mL) and IFN-')' (100 U/mL) in the presence of 0.1 mmollL dbcAMP, or 0.0 I mmollL forskolin, and 100 j.LmollL L-NMMA. As expected, cytokines induced the expression of both ICAM-I and NOS-2 protein, and stimulation of cAMP-dependent signaling potentiated and inhibited NOS-2 and ICAM-I protein expression, respectively (Fig. 5) . Incubation with L-NMMA inhibited the cytokine-induced nitrite release, demonstrating that the L-arginine analog had effectively inhibited NOS-2 activity. However, in the same cells, L-NMMA failed to alter the cAMP-induced reduction of ICAM-I expres sion. This result indicates that the increase in NO pro duction induced by cAMP did not account for the paral lel reduction of ICAM-I expression.
To measure NFKB activation, nuclear extracts were prepared from cells exposed to cytokines or dbcAMP and processed for EMSA using oligonucleotides contain ing consensus or, for control, mutated NFKB binding sites. Because the NOS-2 enzyme had to be synthesized
de novo, we tested short and long incubation times to consider the possibility that the NOS-2-released NO may act on the sustained rather than on the acute NFKB ac tivation. A highly abundant DNA-protein complex of fast mo bility appeared in all samples, both when using consen sus and mutated oligonucleotides, indicating that it did not contain NFKB proteins (labeled as nonspecific in Fig.  6 ). Exposure to cytokines induced the formation of two additional complexes (I and II) at the two times analyzed. Supershift analysis confirmed the presence of the p65 NFKB protein in both complexes (data not shown). The presence of complex II in control cells indicated some constitutive NFKB activation. Addition of dbcAMP did not modify significantly the band pattern detected in the presence of cytokines, nor did it induce NFKB activation on its own. This result indicates that, in BEC, activation of cAMP-dependent signaling does not alter the cyto kine-induced movement of NFKB transcription factor to the nucleus.
DISCUSSION
We have shown that proinflammatory cytokines in duced the expression of NOS-2 and ICAM-I proteins and mRNA in cultured BEC, that cAMP regulated this ex pression, although in an opposite manner, and that the effect of cAMP was independent of NO and NFKB ac tivation. Both IL-l [3 and IFN-)' acted synergistically to induce NOS-2 expression, whereas only IL-l [3 induced an in crease in ICAM-l expression. This result is surprising because IFN-)" alone or in combination with other cy tokines, has been shown to be a potent inducer of ICAM-l expression on many cell types, including astro cytes (Frohman et aI., 1989) , smooth muscle cells (Braun et aI., 1995) , BEC (Fabry et aI., 1992; Wong and Dorovini-Zis, 1992; McCarron et aI., 1993) , and human 30 min 4h 30 min 4h umbilical endothelial cells (Sancho et aI., 1999) . The reasons for the discrepancy between these studies and ours are not clear. Whereas ICAM-l and NOS-2 have been widely stud ied individually, this is the first time that the regulation of the two molecules has been analyzed at the same time. Stimulation of cAMP-dependent signaling had a dual effect on the response to cytokines: it potentiated the expression of NOS-2, whereas it inhibited ICAM-l ex pression, affecting both the mRNA and protein contents. This finding was unexpected because it is believed that the production of these pro inflammatory molecules is regulated in unison, triggered in the early phases of in- flammation, and inhibited in later phases by suppressors of inflammation (Vodovotz et al., 1993; Bogdan et a1., 1994; Shimizu et al., 1999) . Experiments were conducted in primary endothelial cell cultures, and in the immortalized endothelial cell line GP8.3, to determine whether the latter, much easier to generate, can be used as a model for blood-brain barrier inflammation. Several differences were found in the re sponses of the two cell types. First, in primary cultures rL-l � alone induced expression of NOS-2 and IFN-')' greatly potentiated this effect, whereas in the GP8.3 cells, NOS-2 expression was elicited only in the presence of both cytokines. Second, cAMP potentiated NOS-2 ex pression in primary cultures when the inflammatory stimulus was IL-I � but not in the presence of IL-l � and IFN-')'. By contrast, cAMP could potentiate the effect of IL-I � plus IFN-')' in GP8.3. cells. These observations suggest that, in primary cultures but not in GP8.3 cells, the NOS-2 expression elicited by the combination of the two cytokines was maximal, and thus it could not be further increased by stimulation of cAMP-dependent pathways. It thus appears that the sensitivity to cytokines may be reduced in GP8.3 cells with respect to the pri mary endothelial cell cultures, perhaps because of the loss of cytokine receptors.
Another difference observed was related to the ef fect of the drugs used to stimulate cAMP-dependent pathways. Thus, dbcAMP was the most potent inhibitor of lCAM-l expression in primary cultures, whereas for skolin was the most effective in GP8.3 cells. Unlike dbcAMP, which is a nonmetabolizable cAMP analog, forskolin causes a transient increase in the content of intracellular cAMP because of the actions of phosphodi esterases. Conceivably, some phosphodiesterase activi ties may have been lost in the generation of the GP8.3 cells, thereby explaining the greater effectiveness of for skolin. Although these findings reveal differences be tween primary and immortalized endothelium regarding cAMP-dependent signaling, the effect of cAMP on NOS-2 and ICAM-I expression was similar in both cells types. We thus conclude that the GP8.3 cells can be used instead of the primary cultures to gain insight into mechanisms of action of this second messenger.
Stimulation of cAMP-dependent pathways can inhibit adhesion molecule expression in several cell types. Thus, elevation of intracellular cAMP reduces the TNF-O'-or rL-l �-mediated upregulation of ICAM-I and VCAMI in smooth muscle cells (Panettieri et al., 1995) and as trocytes (Ballestas and Benveniste, 1997) . Also, cAMP antagonizes the TNF-O'-mediated expression of endothe lial leukocyte adhesion molecule, ELAM I, and vascular cell adhesion molecule, VCAM 1, in human BEC (Pober et aI., 1993; Ghersa et al., 1994) . Reports on the effect of cAMP on ICAM-l expression in endothelial cells are, however, conflicting. Whereas one group has found suppression (Ochi et aI., 1995) , others report potentiation (Ghersa et aI., 1994) or no effect (Deisher et al., 1993; Pober et al., 1993; Morandini et al., 1996) . These obser vations, together with ours, reveal that cAMP-dependent signaling exerts a widespread modulatory-mostly sup pressive-action on the expression of adhesion mol ecules in the course of inflammatory activation, although differences exist, depending on the cell and adhesion molecule being analyzed. Expression of NOS-2 also is widely regulated by cAMP. However, cAMP can play stimulatory or inhibitory roles, depending on the cell type (for review see Galea and Feinstein, 1999) . Thus, endotoxin-or cytokine-mediated NOS-2 mRNA and NOS-2 protein expression is inhibited by cAMP in glial (Feinstein et aI., 1993) , pancreatic, and liver cells (Andersen et aI., 1996; Harbrecht et aI., 1996) . By con trast, increased cAMP stimulates NOS-2 expression in smooth muscle cells (Eberhardt et aI., 1998) , adipocytes (Nisoli et aI., 1997) , and, as shown here, BEe.
For both rCAM-l and NOS-2, protein and mRNA contents changed in parallel after increasing intracellular cAMP. This suggests that cAMP-dependent pathways target pre-translational events such as regulation of mRNA stability or gene transcription. The 3' untrans lated regions of both the rCAM-1 (Wertheimer et al., 1992) and the NOS-2 (Galea et aI., 1994) mRNA contain several AUUUA motifs. These sequences modulate mRNA turnover and are typically abundant in short-lived mRNA (Kruys et aI., 1990) . However, evidence in other cell types demonstrates that regulation of rCAM -1 (Oc chi et al., 1995; Ballestas and Benveniste, 1997) and NOS-2 (Eberhardt et aI., 1998) expression by cAMP oc curs primarily at the level of gene transcription. We thus speculate that, in brain endothelium, the changes in pro duction of NOS-2 and rCAM-I protein and mRNA also occur via changes in the transcriptional rates of the cor responding genes.
The question then arises as to how cAMP-dependent pathways exert opposite effects on the transcription of the ICAM-I and NOS-2 genes. One possibility is that the increase in NOS-2 and the decrease of ICAM-l were causally related. It is well established that NO can inhibit leukocyte adhesion to the vascular walls under basal con ditions or during inflammation. Studies using NO donors or NOS inhibitors have demonstrated that NO acts by suppressing the expression of adhesion molecules such as platelet endothelial adhesion molecule, VCAM 1, P selectin, and ICAM-I (Luvara et aI., 1998; Liu et aI., 1998; Scalia and Lefer, 1998; Lefer et aI., 1999) . The mechanism of action of NO appears to be the reduction of gene transcription by blockade of NFKB activation (De Caterina et al., 1995; Khan et aI., 1996; Kupatt et aI., 1997) , either by scavenging reactive oxygen species (Kupatt et aI., 1997) or by upregulation of the endog enous inhibitor of NFKB, IKB-O' (Spiecker et al., 1998) .
Considering this evidence, it is tempting to hypothesize that the NO derived from NOS-2 causes the inhibition of ICAM-l expression. However, inhibition of NOS-2 ac tivity did not prevent the cAMP-mediated down regulation of ICAM-l expression, nor did it alter NFKB activation. These results suggest that, unlike in periph eral endothelium, NO does not play an anti adhesive role in brain endothelium. Alternative interpretations are, nevertheless, possible. First, NO could decrease expres sion of adhesion molecules other than ICAM-I. Prece dents for this exist in saphenous endothelial cells, where NO donors inhibited the expression of VCAMI and E selectin but not ICAM-l (De Caterina et aI., 1995) , and in human lung microvascular cells, in which increases in intracellular cAMP by phosphodiesterase inhibitors de creased the cytokine-induced expression of E-selectin but did not alter ICAM-l expression (Blease et aI., 1998) . Second, down-regulation of ICAM-l by NO may occur in resting conditions but not during inflammation. This has been observed in vitro in human umbilical en dothelial cells (Biffl et aI., 1996) and in an in vivo model of acute inflammation (Cockrell et aI., 1999) .
Alternatively, it has been proposed in peripheral en dothelial cells that the inhibitory effect of cAMP on ad hesion molecule expression is mediated by cAMP re sponse element binding protein (CREB), the transcrip tion factor activated by protein kinase A (Parry and Mackman, 1997) . The evidence suggests that CREB may block the transcriptional activity of the NFKB migrated to the nucleus by quenching essential transcriptional co activators (Parry and Mackman, 1997) . Evidence also indicates a role for CREB in the upregulation of NOS-2 by cAMP. Thus, in smooth muscle-derived cells, analy sis of the activity of serial deletion constructs of the NOS-2 promoter, combined with site-directed mutagen esis, reveals that binding of CREB to the site of another transcription factor, C/EBP, accounts for the stimulatory effects of cAMP (Eberhardt et aI., 1998) . Whether these mechanisms apply to brain endothelium remains to be determined.
Considering that the upregulation of ICAM-l exacer bates the damage in the course of brain disorders with inflammatory components (e.g., ischemia or demyelinat ing diseases [Archelos et aI., 1993; Morrisey et aI., 1996; Chopp et aI., 1996; Soriano et aI., 1996] ), the inhibitory actions of cAMP-dependent signaling should result in protection. Less clear is the role of the parallel upregu lation of NOS-2 expression, since blockade of NOS-2 activity in vivo results in both amelioration (Cross et aI., 1994; Nagayama et aI., 1998) and worsening of brain diseases (Ruuls et aI., 1996) . The discrepancy may arise from the fact that NOS-2 is expressed in different cell types, namely glial cells, macrophages, and endothelial cells, in association with various brain disorders (En doh et aI., 1994; Cross et aI., 1994; Iadecola et aI., 1996;  J Cereb Blood Flow Metab. Vol. 20. No.4. 2000 Olesza k et aI., 1997; Galea et aI., 1998b) . Because of the highly cytotoxic effects of NO when combined with oxy gen radicals, expression of NOS-2 generally is believed to generate further da mage. Whereas strong evidence in dicates that this may be the case for NOS-2 expressed in macrophages (MacMicking et aI., 1997), the NO locally released by endothelial NOS-2 may, by contrast, reduce the brain damage by virtue of its vasodilatory (Loscalzo et aI., 1995) and, perhaps, its antiadhesive actions, as discussed earlier. If so, the dual effect of cAMP on the expression of NOS-2 and ICAM-l in brain endothelium could result in neuroprotection.
It has long been recognized that cAMP-dependent pathways play a role in the regulation of brain microvas cular function (Palmer et aI., 1986; Cohen et aI., 1996) . Brain microvessels, including capillaries, arterioles, and venules, are innervated by serotoninergic (l takura et aI., 1985; Cohen et aI., 1995) , noradrenergic (Cohen et aI., 1997) , and VIPergic neurons (Paspalas and Papadopou los, \998), all of which release neurotransmitters that act via cAMP. Local application of serotonin or noradrena line, or manipulation of nuclei where perivascular fibers originate, results in changes in blood-brain barrier per meability or local blood flow (Palmer et aI., 1986; Sharma et aI., 1986; Sarmento et aI., 1991) . Whereas the vascular smooth muscle cells account for the latter, al terations in permeability are conceivably confined to the endothelial compartment. The ability of endothelial cells to respond directly to the perivascular fibers is under scored by anatomical, biochemical, and functional evi dence. First, there is direct apposition of nerve terminals to the endothelial cell basal membrane (Cohen et aI., 1997; Pas pal as and Papadopoulos, 1998) . Second, BEC have receptors for serotonin (Bacic et aI., 1991) , VIP (Martin et aI., 1992) , and noradrenaline (Karnushina et aI., 1982; Durieu-Trautmann et aI., 1991) , coupled to cAMP synthesis. Finally, the elevation of cAMP in en dothelial cell cultures decreases the transcellular perme ability (Borges et aI., 1994; Rist et aI., 1997; Hurst and Clark, 1998) . Our observation that cAMP-dependent pathways in BEC control the cytokine-mediated expres sion of ICAM-l and NOS-2 supports the idea, originally developed in a previous study (Galea et aI., 1998a) , that, in addition to controlling blood flow and permeability, locally released neurotransmitters may regulate inflam matory reactions at the blood-brain barrier.
